NCT03301220: Phase 3: A Study of Subcutaneous Daratumumab Versus Active Monitoring in HI Risk SMM
Updated: May 23, 2022
NCT03301220: Phase 3: A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk smoldering multiple myeloma (SMM).
Sponsor
Janssen Research & Development, LLC
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT03301220
Official Title: A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects With High-Risk Smoldering Multiple Myeloma
First Posted : October 4, 2017
Click here for details on ClinicalTrials.gov
Drug: Daratumumab SC: daratumumab + rHuPH20
Locations
United States, Arizona
United States, California
United States, Florida
United States, Georgia
United States, Iowa
United States, Louisiana
United States, Massachusetts
United States, Michigan
United States, Minnesota
United States, Missouri
United States, Nevada
United States, New York
United States, North Carolina
United States, Ohio
United States, Oregon
United States, Pennsylvania
United States, Texas
United States, Washington
Mexico
Canada, Alberta
Canada, Ontario
Argentina
Brazil
Europe
United Kingdom
Czechia
Denmark
France
Germany
Greece
Italy
Netherlands
Norway
Poland
Sweden
Spain
Belgium
Hungary
Russian Federation
Asia
Turkey
Israel
Japan
Australia